Literature DB >> 29884434

Mortality in people with mental disorders in the Czech Republic: a nationwide, register-based cohort study.

Dzmitry Krupchanka1, Karolína Mladá2, Petr Winkler3, Yasser Khazaal4, Emiliano Albanese4.   

Abstract

BACKGROUND: The region of central and eastern Europe is estimated to have high rates of premature mortality due to mental disorders. However, epidemiological evidence is scarce and insufficient to inform policy actions and health system development. We aimed to assess mortality associated with mental disorders in the Czech Republic.
METHODS: We did a nationwide, register-based, retrospective cohort study using routinely collected health data from two nationwide registries in the Czech Republic: the register of inpatient discharges (from Jan 1, 1994, to Dec 31, 2013) and the causes of death registry (from Jan 1, 1994, to Dec 31, 2014). We first identified all individuals discharged from mental health institutions with WHO International Classification of Diseases tenth edition (ICD-10) diagnoses of mental and behavioural disorders (from 1994 to 2013). We then did a deterministic individual-level linkage of these data with all-cause mortality data for the whole period (1994-2014). Standardised mortality ratios (SMRs) and 95% CIs were calculated for the year 2014, comparing deaths in people with mental and behavioural disorders discharged from psychiatric hospitals with deaths in the general population.
FINDINGS: The final study population comprised 283 618 individuals. 3819 of these individuals died in 2014, corresponding to a mortality risk more than two times higher than that of the general population (SMR estimate 2·2; 95% CI 2·2-2·3). Differences in SMR estimates across diagnostic groups were substantial, with the highest SMR for substance use disorders (3·5; 95% CI 3·4-3·7) followed by schizophrenia, schizotypal, and delusional disorders (2·3; 2·1-2·5), personality disorders (2·3; 2·0-2·6), neurotic, stress-related, and somatoform disorders (1·8; 1·6-1·9), and mood (affective) disorders (1·6; 1·5-1·7).
INTERPRETATION: Mortality among people with mental disorders in the Czech Republic is markedly higher than in the general population. Our findings should stimulate and inform policy in the central and eastern Europe region, as well as ongoing national mental health-care reforms in the Czech Republic. FUNDING: Czech Ministry of Education, Youth and Sports.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29884434     DOI: 10.1016/S2468-2667(18)30077-X

Source DB:  PubMed          Journal:  Lancet Public Health


  4 in total

1.  Disparities in the Use of General Somatic Care among Individuals Treated for Severe Mental Disorders and the General Population in France.

Authors:  Coralie Gandré; Magali Coldefy
Journal:  Int J Environ Res Public Health       Date:  2020-05-12       Impact factor: 3.390

2.  Investigation of risk of dementia diagnosis and death in patients in older people's secondary care mental health services.

Authors:  Anne Kershenbaum; Rudolf N Cardinal; Shanquan Chen; Benjamin R Underwood; Aida Seyedsalehi; Jonathan Lewis; Judy Sasha Rubinsztein
Journal:  Int J Geriatr Psychiatry       Date:  2020-11-04       Impact factor: 3.485

3.  Correlates of self-reported history of mental health help-seeking: a cross-sectional study among individuals with symptoms of a mental or substance use disorder initiating care for HIV in Cameroon.

Authors:  Lindsey M Filiatreau; Peter Vanes Ebasone; Anastase Dzudie; Rogers Ajeh; Brian Pence; Milton Wainberg; Denis Nash; Marcel Yotebieng; Kathryn Anastos; Eric Pefura-Yone; Denis Nsame; Angela M Parcesepe
Journal:  BMC Psychiatry       Date:  2021-06-05       Impact factor: 3.630

4.  Impact of history of mental disorders on short-term mortality among hospitalized patients with sepsis: A population-based cohort study.

Authors:  Lavi Oud; John Garza
Journal:  PLoS One       Date:  2022-03-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.